• Agency Unveils RaDaR to Help Patient Groups Develop Rare Disease Registries
  • Mild Inhibition of Mitochondria Reduces Susceptibility to Seizure in Mice with Dravet Syndrome, Study Shows
  • Rare Diseases Constitute a ‘Public Health Issue,’ NCATS Director Warns
  • #AANAM – Epidiolex Reduces Frequency of Seizures in Children with Dravet Syndrome, Phase 3 Trial Shows
  • Ketogenic Diet May Reduce Sudden Unexpected Deaths in Epilepsy, Mouse Study Suggests
  • Diacomit Tops List of Add-on Therapies to Control Epileptic Seizures in Children With Dravet, Review Study Says
  • FDA Refuses New Drug Application for Zogenix’s Fintepla (ZX008)
  • Dravet Syndrome Patients Exhibit Variety of Gait Alterations, Review Finds
  • Anti-seizure Effects of Cannabinoids May Benefit Some Neurological Disorders But Not Others, Review Study Says
  • Cannabis-derived Epidiolex Cleared for Clinical Trials in Japan for Dravet, Lennox-Gastaut Syndromes
  • Nippon Shinyaku to Market Fintepla in Japan for Treatment of Dravet Syndrome Seizures
  • Dravet Syndrome’s Impact on Quality of Life May be Generalized for Patients, Caregivers Across the West, Study Suggests